BMC Dermatology最新文献

{"title":"A seven-year retrospective analysis of patch test data in a cohort of patients with contact dermatitis in Sri Lanka.","authors":"B S D P Keragala,&nbsp;H M M T B Herath,&nbsp;T S Keragala,&nbsp;M A M H Malavi,&nbsp;Chaturaka Rodrigo,&nbsp;C N Gunasekera","doi":"10.1186/s12895-019-0090-8","DOIUrl":"https://doi.org/10.1186/s12895-019-0090-8","url":null,"abstract":"<p><strong>Background: </strong>Patch testing with a baseline series is a common tool employed when the sensitizing agent in contact dermatitis is unclear. However, for Asian countries, there are no locally validated baseline series to utilize in screening.</p><p><strong>Methods: </strong>We completed a retrospective analysis of all patients that had undergone patch testing with the European Baseline series, Shoe Series or Comprehensive International Baseline series, over 7 years from 2012 to 2018 in a tertiary care reference dermatology clinic in Sri Lanka to evaluate the suitability of these investigations to identify causes for contact dermatitis in the local study population.</p><p><strong>Results: </strong>Out of 438 patients tested, 239 (54.8%) reacted to at least one substance in the series. The Shoe Series was significantly more likely to yield a positive result than the European Baseline Series (70.2% vs 46.9%, p < 0.05). The top three sensitizers identified by all series were nickel sulfate (16%, 70/438), p-phenylenediamine (12.3%, 54/438) and 2-mercaptobenzothiazole or mercapto mix (10.5%, 46/438).</p><p><strong>Conclusion: </strong>Shoe series has a comparatively high yield in the local population compared to European Baseline series. Since little less than half of the study population did not have any reactivity to any of the allergens tested it is important to develop or modify and validate a locally relevant, more suitable baseline series which is based on the Shoe Series in Sri Lanka. This is further evidence for the continuously changing nature of allergens in the environment and the need to modify existing patch testing standards accordingly.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2019-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0090-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37133831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diaper dermatitis: a survey of risk factors in Thai children aged under 24 months.","authors":"Chonnakarn Sukhneewat,&nbsp;Jitjira Chaiyarit,&nbsp;Leelawadee Techasatian","doi":"10.1186/s12895-019-0089-1","DOIUrl":"https://doi.org/10.1186/s12895-019-0089-1","url":null,"abstract":"<p><strong>Background: </strong>To identify the prevalence and risk factors associated with diaper dermatitis in Thai children aged 1-24 months.</p><p><strong>Methods: </strong>This was a cross-sectional study of 1153 participants using structural questionnaires, which was conducted at Khon Kaen University Faculty of Medicine Pediatric department in Thailand. Univariate and multivariate logistic regression analyses were used to test the association between diaper dermatitis and its possible risk factors.</p><p><strong>Results: </strong>The prevalence of diaper dermatitis among the study population was 36.1%, a rate which significantly decreased with age. The highest prevalence was found in subjects who were one to six months old. Risk factors that had a statistically significant association with diaper dermatitis in both univariate and multivariate analysis were i) diaper changing fewer than three times/night, ii) previous episodes of diaper rash, iii) using cloth diapers, and iv) topical application of baby talcum powder to the diaper area.</p><p><strong>Conclusions: </strong>Frequent diaper changings during the daytime do not compensate for fewer changings during the night. Moreover, the use of baby talcum powder on the diaper area significantly increased the risk of diaper dermatitis among the study population. These findings should be applied in future preventive strategies for diaper dermatitis in this age group.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2019-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0089-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37381520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.","authors":"Kim A Papp,&nbsp;Melinda Gooderham,&nbsp;Jennifer Beecker,&nbsp;Charles W Lynde,&nbsp;Isabelle Delorme,&nbsp;Ignacio Dei-Cas,&nbsp;Lorne Albrecht,&nbsp;Emmanouil Rampakakis,&nbsp;John S Sampalis,&nbsp;Antonio Vieira,&nbsp;Shamiza Hussein,&nbsp;Olivier Chambenoit,&nbsp;Lenka Rihakova","doi":"10.1186/s12895-019-0087-3","DOIUrl":"https://doi.org/10.1186/s12895-019-0087-3","url":null,"abstract":"<p><strong>Background: </strong>Treatment options for the management of moderate to severe plaque psoriasis include phototherapy, oral systemic agents, and biologic therapy. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A, is the first IL-17 antagonist approved for this patient population. Long-term observational data are required for establishing the true population-based benefit-risk ratio of approved treatments. PURE is a multinational registry that will assess the real-world safety and effectiveness of secukinumab and other approved therapies in the management of patients with moderate to severe psoriasis.</p><p><strong>Methods: </strong>This is a multinational (Canadian and Latin American), prospective, observational study of adult patients with moderate to severe psoriasis that initiate treatment with secukinumab or other approved therapies as per local standard of care. A total of 2500 patients (1250 per cohort) will be recruited in the practices of hospital and community dermatologists. Decision regarding treatment must have been reached prior to and independent of patient enrollment in the study. The study includes a 5-year follow-up with recommended assessments at Baseline, 3 and 6 months post-Baseline, and every 6 months thereafter. The primary objective of the study is safety. Secondary outcome measures relate to effectiveness (Investigator's Global Assessment -IGA mod 2011-, Psoriasis Areas and Severity Index, Body Surface Area), patient reported outcomes (Dermatology Life Quality Index, Work Productivity and Activity Impairment Questionnaire, Hospital Anxiety and Depression Scale, Psoriasis Epidemiology Screening Tool, Psoriasis Symptom Diary, and Treatment Satisfaction Questionnaire), and healthcare resource utilization.</p><p><strong>Discussion: </strong>This is the first observational study in Canada and Latin America assessing the real-world safety and effectiveness of secukinumab in the management of moderate to severe psoriasis. The extensive clinical, patient-reported and health economic outcomes collected will allow the comprehensive evaluation of this new treatment in comparison to other approved therapies.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02786186 ; date of registration: May 30, 2016.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2019-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0087-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37358071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.","authors":"Kristina Callis Duffin,&nbsp;Andrew G Bushmakin,&nbsp;Joseph C Cappelleri,&nbsp;Lotus Mallbris,&nbsp;Carla Mamolo","doi":"10.1186/s12895-019-0088-2","DOIUrl":"https://doi.org/10.1186/s12895-019-0088-2","url":null,"abstract":"<p><strong>Background: </strong>Several different Physician Global Assessment (PGA) versions have been used in clinical studies as a co-primary end point to evaluate psoriasis severity. Tofacitinib is an oral Janus kinase inhibitor. We performed an analysis of the PGA using data from studies of tofacitinib in moderate to severe chronic plaque psoriasis.</p><p><strong>Methods: </strong>Data from 3641 patients with moderate to severe chronic plaque psoriasis, enrolled in one of four phase III tofacitinib studies (OPT Pivotal 1 and 2, OPT Compare and OPT Retreatment), were used to evaluate a three-item PGA scale.</p><p><strong>Results: </strong>Confirmatory Factor Analyses showed that equal weighting of the three items (erythema, induration and scaling) was appropriate. The PGA demonstrated acceptable test-retest reliability (Intraclass Correlation Coefficient, 0.7) and internal consistency (Cronbach's Coefficient Alpha ≥ 0.9 at primary time points). The Clinically Important Difference was estimated as 0.55 (95% confidence interval: 0.546-0.563). Known-group validity was shown by demonstrating that PGA scores could discriminate between different degrees of disease severity. The PGA was significantly correlated with other clinical end points in the studies (Psoriasis Area and Severity Index, r = 0.75-0.79; Dermatology Life Quality Index, r = 0.44-0.57; Patient Global Assessment, r = 0.66-0.72).</p><p><strong>Conclusions: </strong>Consistent with previous findings from a phase II study, these results indicate that this PGA is a valid, reliable instrument for evaluating disease severity in clinical studies of psoriasis.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2019-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0088-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37034906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sofosbuvir induced leucocytoclasic vasculitis: a case report.","authors":"Elena Campione,&nbsp;Annunziata Dattola,&nbsp;Monia Di Prete,&nbsp;Daniele Di Paolo,&nbsp;Amedeo Ferlosio,&nbsp;Augusto Orlandi,&nbsp;Luca Bianchi","doi":"10.1186/s12895-019-0086-4","DOIUrl":"https://doi.org/10.1186/s12895-019-0086-4","url":null,"abstract":"<p><strong>Background: </strong>We describe a case of leucocytoclasic vasculitis induced by Sofosbuvir and its disappearence after the end of the therapy. The hepatitis C virus, firstly described in 1989, is a major global health problem, with high morbidity and mortality. We observed a temporal relationship between the treatment and the onset of vasculitis. We emphasize the multidisciplinary approach to the patients with liver disease to improve the quality of life of these patients.</p><p><strong>Case presentation: </strong>A 53-year-old Caucasian man with a history of hepatitis C virus genotype 1 infection was examined at our Department of Dermatology for the occurrence of palpable purpura. The patient referred that the first appearance of the dermatoses was about one month after initiation of therapy with Sofosbuvir for hepatitis C.</p><p><strong>Conclusions: </strong>Vasculitis appeared after the beginning of Sofosbuvir and, even though it was treated with different medications proved to be effective, it disappeared only after the conclusion of the therapy, giving a strong evidence to be a drug eruption.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2019-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0086-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37247820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern of skin diseases in children attending a dermatology clinic in a referral hospital in Wolaita Sodo, southern Ethiopia.","authors":"Abraham Getachew Kelbore,&nbsp;Philip Owiti,&nbsp;Anthony J Reid,&nbsp;Efa Ambaw Bogino,&nbsp;Lantesil Wondewosen,&nbsp;Blen Kassahun Dessu","doi":"10.1186/s12895-019-0085-5","DOIUrl":"10.1186/s12895-019-0085-5","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies to determine the pattern of skin diseases among children are important for proper health care planning and management. The purpose of this study was to describe the pattern of skin diseases among pediatric patients seen at a dermatology outpatient clinic of Wolaita Sodo Teaching and Referral Hospital, southern Ethiopia.</p><p><strong>Method: </strong>We conducted a retrospective hospital-based, cross-sectional study between January 2016 and December 2017 at a teaching and referral hospital dermatology outpatient department. All children younger than 15 years presenting with newly-diagnosed skin diseases were included. Diagnosis was mainly made clinically, with some laboratory support.</p><p><strong>Results: </strong>A total of 1704 children with 1869 new skin diagnoses were included, of whom 139 (8.2%) had more than one disease. Of the children, 52.4% were males and 44.9% within the age-group 5-10 years. Eczematous dermatitis accounted for the largest group (23.9%, n = 447) of skin conditions followed by bacterial infections (21.3%, n = 398), fungal infections (18.8%, n = 351) and infestations (9.9%, n = 185). Seasonal variation was demonstrated, with eczematous conditions and bacterial infections being higher during autumn and winter.</p><p><strong>Conclusion: </strong>Overall, eczema, bacterial and fungal infections were the three major pediatric skin diseases occurring among children attending this hospital's outpatient department. There was seasonal variation in some of the skin diseases. This study gives a snapshot of skin disorders presenting to hospital in children in southern Ethiopia and may help to plan dermatology service expansion, educational programs and preventive measures.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2019-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0085-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37131612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel elastin gene frameshift mutation in a Russian family with cutis laxa: a case report.","authors":"E G Okuneva,&nbsp;A A Kozina,&nbsp;N V Baryshnikova,&nbsp;A Yu Krasnenko,&nbsp;K Yu Tsukanov,&nbsp;O I Klimchuk,&nbsp;E I Surkova,&nbsp;V V Ilinsky","doi":"10.1186/s12895-019-0084-6","DOIUrl":"https://doi.org/10.1186/s12895-019-0084-6","url":null,"abstract":"<p><strong>Background: </strong>Cutis laxa (CL) is a rare connective tissue disorder characterized by loose, redundant, inelastic and wrinkled skin. Patients develop a prematurely aged appearance. Inheritance can be autosomal dominant or autosomal recessive. The X-linked form is now classified in the group of copper transport diseases. Autosomal dominant CL is characterized by wrinkled, redundant and sagging, inelastic skin and in some cases is associated with internal organ involvement.</p><p><strong>Case presentation: </strong>We report a familial case of autosomal dominant CL, which includes a 33-year-old woman and her 11-year-old son with dry, thin and wrinkled skin that appeared prematurely aged. No serious involvement of internal organs was found. In both patients, we identified novel heterozygous mutation c.2323delG (p.Ala775fs) in exon 34 of elastin transcript NM_001278939.1. Similar frameshift mutations in the last exons of elastin gene were previously reported in patients with autosomal dominant CL.</p><p><strong>Conclusions: </strong>Our results show a novel frameshift mutation that was found in patients with cutis laxa. Exome sequencing is effective and useful technology for properly diagnosis of diseases with similar phenotype to ensure proper treatment is provided.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2019-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0084-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36917803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucous membrane pemphigoid-associated paronychia with onychomadesis.","authors":"Salim Alkeraye,&nbsp;Sarah F Alsukait","doi":"10.1186/s12895-019-0083-7","DOIUrl":"https://doi.org/10.1186/s12895-019-0083-7","url":null,"abstract":"<p><strong>Background: </strong>Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease that is notoriously difficult to treat. Nail involvement in MMP is rare.</p><p><strong>Case presentation: </strong>We report on a 58 years old man with severe MMP who presented with onychomadesis.</p><p><strong>Conclusion: </strong>To our knowledge, mucous membrane pemphigoid associated paronychia and onychomadesis have not been reported before. We believe it is important for dermatologists to be aware of this entity.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2019-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0083-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36889829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proderm technology: a water- based lipid delivery system for dermatitis that penetrates viable epidermis and has antibacterial effects.","authors":"Alexandra Charruyer,&nbsp;Mats Silvander,&nbsp;Melinda Caputo-Janhager,&nbsp;Isabelle Raymond,&nbsp;Ruby Ghadially","doi":"10.1186/s12895-019-0082-8","DOIUrl":"https://doi.org/10.1186/s12895-019-0082-8","url":null,"abstract":"<p><strong>Background: </strong>A defective skin barrier and bacterial colonization are two important factors in maintenance and progression of atopic dermatitis and chronic allergic/irritant hand dermatitis. A water-based lipid delivery system containing physiologic lipids was previously shown to be a useful adjunct in the treatment of hand dermatitis. We tested the ability of this formulation to penetrate into the viable epidermis and in addition assessed its antibacterial properties.</p><p><strong>Methods: </strong>Epidermal penetration of the product was assessed by fluorescence microscopy. Recovery of Escherichia coli and Staphylococcus aureus MRSA from skin treated with Neosalus® foam was quantified.</p><p><strong>Results: </strong>Components of Neosalus® penetrated the stratum corneum and were distributed throughout the viable epidermis. Neosalus® significantly decreased recovery of both Staphylococcus aureus and Escherichia coli from the skin surface.</p><p><strong>Conclusions: </strong>The ability of components of Neosalus® to be taken up into the viable epidermis and potentially made available for incorporation into the barrier lipids, combined with antibacterial properties, indicate that this formulation may be valuable not only in chronic hand dermatitis, but also in various other forms of dermatitis.</p><p><strong>Trial registration: </strong>Current Controlled Trials ISRCTN18191379 , 28/12/2018, retrospectively registered.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2019-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-019-0082-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36886835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in microRNA expression between melanoma and healthy adjacent skin.","authors":"Mariya Aksenenko,&nbsp;Nadezhda Palkina,&nbsp;Anna Komina,&nbsp;Liubov Tashireva,&nbsp;Tatiana Ruksha","doi":"10.1186/s12895-018-0081-1","DOIUrl":"https://doi.org/10.1186/s12895-018-0081-1","url":null,"abstract":"<p><strong>Background: </strong>The tumor microenvironment is composed of cancer-associated fibroblasts, tumor-associated macrophages, endothelial cells, immune cells, signaling molecules and extracellular matrix structures, which closelycommunicate with the tumor via multiple mechanisms. MicroRNAs are paracrine regulators that provide a direct interaction between the microenvironment and cancer cells. In the presentstudy, we aimed to identify the microRNA expression profile in melanoma compared with thatin healthy adjacent skin, with a further assessment of altered microRNA signaling pathways and target genes.</p><p><strong>Methods: </strong>Formalin-fixed paraffin-embedded (FFPE) melanoma tissue samples were separated by dissection into tumor and surrounding health tissue fragments. MicroRNA expression profiles were obtained by microarray using Gene Atlas Microarray System (Affymetrix, California, USA). To confirm microarray results real-time PCR was carried out. Bioinformatic analysis was performed using the DIANA-miRPath v.3.0 database. Target genes for miR-146a-5p were determined using three algorithms: TargetScan 7.0, miRWalk 2.0 and miRTarBase v.4.5.</p><p><strong>Results: </strong>A microarray profiling revealed 143 microRNAs asdifferent in tumor versus adjacent tissues. Expression level of hsa-miR-146a-5p showedto be higher in melanoma cells as compared to thehealthy adjacent skin. The bioinformatic study has determined several signaling cascades associated with miR-146a-5p:Toll-like receptor pathway, NF-κB pathway, ErB pathway, and measles signaling pathway. The 38 target genes have been shown for miR-146a-5p of which NRAS gene is known asone of the most frequent mutated in melanoma.</p><p><strong>Conclusions: </strong>Elucidation of the role of miR-146-a-5p in complex interactions between the tumor and the cells of healthy adjacent skin is necessary for our understanding of the mechanisms oftumor progression. Significant differences found between cancer cells and adjacent tissues in microRNA expression profile corresponding to divergent mRNA/protein levels in these structures should be taken into account when tumor samples characterization estimatedby high-throughput methods.</p>","PeriodicalId":9014,"journal":{"name":"BMC Dermatology","volume":"19 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2019-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12895-018-0081-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36835635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}